Cosmetic Claims Substantiation: The Evidence Behind “Clinically Proven” and “Dermatologist Tested”

A cosmetic claim is only as strong as the evidence file behind it. If a listing says “clinically proven” or “dermatologist tested,” the useful question is not whether the phrase is allowed. It is whether you can produce the study, the tested formula, the population, the endpoint and the result that support that exact sentence. In the US, ordinary cosmetic claims are not pre-approved by FDA, and the FTC does not clear advertising before it runs. The FTC requires a reasonable basis before an objective claim is published, and a claim that advertises a level of proof requires at least that level of proof. That is the work of cosmetic claims substantiation: matching each sentence to the evidence that supports it.

The short answer

Three rules cover most of the work:

1. Substantiate before you publish. The file has to exist when the claim runs, not after a retailer, a competitor or the FTC asks for it.
2. Match the phrase to the evidence. “Clinically proven” commits you to clinical evidence for that product and that benefit. “Dermatologist tested” commits you to a documented dermatologist role in the testing. “Hypoallergenic” is not a certified status.
3. Do not use a disclaimer as a repair kit. Qualifying language can clarify a truthful claim. It cannot make an unsupported claim supported.

If you cannot produce the file, change the claim. A weaker true sentence is easier to defend than a stronger one you cannot back.

What US law requires before the claim goes live

The FTC Act prohibits deceptive advertising. The FTC's substantiation policy states the core rule plainly: advertisers must have a reasonable basis for their claims before those claims are disseminated. The same policy addresses claims that advertise the amount or type of support behind the product. When the substantiation claim is express — the policy gives “tests prove,” “doctors recommend” and “studies show” as examples — the advertiser must have at least the advertised level of substantiation.

FDA operates on a different axis. The agency does not require pre-market approval of cosmetic labeling, and it does not publish a list of approved cosmetic claims. What FDA does require is that labeling, including claims, be truthful and not misleading. FDA also draws the cosmetic-versus-drug line by intended use: a product marketed to treat or prevent disease, or to affect the structure or function of the body, is a drug and must meet drug requirements, even if it also affects appearance.

Those two regimes overlap in practice. A sentence can be a platform-policy problem, an FTC deception problem, an FDA drug-classification problem, or all three. That is why a wording swap alone is a weak fix: the exposure usually sits in the evidence and in what the sentence promises, not only in the adjective.

“Clinically proven” is a promise about the evidence

“Clinically proven” is not a stronger version of “clinically tested.” It tells the reader that clinical evidence supports the specific benefit being advertised. The FTC has treated that as an establishment claim: the advertiser must hold the level of evidence the claim conveys. In its health-products guidance, the FTC says that substantiation of health-related benefits will generally need to be randomized, controlled human clinical testing, and that sample size, duration and outcome measures all affect reliability.

The agency's 2014 case against L'Oréal shows how the analysis works on a cosmetic. The FTC alleged that ads for Lancôme Génifique said the product was “clinically proven” to boost genes' activity and stimulate production of youth proteins, producing “visibly younger skin in just 7 days,” and cited results for specific percentages of users. The settlement prohibited those claims unless the company held competent and reliable scientific evidence for them. It was a settlement, not a court verdict, but the lesson is direct: the phrase was judged against the science behind the mechanism, not against the elegance of the copy.

Hypothetical example: a serum says “clinically proven to reduce wrinkles by 37%.” The file contains a 12-person moisturization reading taken 24 hours after a single application. That study may support a short-term hydration claim. It does not support a 37% wrinkle reduction claim, because it did not measure wrinkles, did not run long enough to see a structural change, and did not test the percentage in the sentence. The fix is not to add “results may vary.” The fix is to describe what the study actually measured, or to run a study that measures the promised endpoint.

The substantiation file: what to request from your manufacturer

Private-label and white-label sellers are usually the advertiser, even when the study was commissioned by the factory. A supplier's one-page “clinical summary” is a marketing document. Ask for the underlying file and keep it with the claim it supports. Cosmetic claims substantiation is a document exercise before it is a copy exercise.

1. The protocol and the full report. You need the objective, the design, the schedule and the results — not a slide with a percentage and a stock photo of a lab.
2. The formula that was tested. Confirm the formula, concentration of key ingredients, and package match the product you sell. If the formula changed after the study, you need a bridging study or a narrower claim.
3. The population and inclusion criteria. Age range, skin type, baseline condition and exclusion criteria determine who the result applies to. A study in 20-year-olds with normal skin does not automatically support a claim aimed at menopausal skin.
4. The endpoints and how they were measured. Instrumental measurement, blinded clinical grading and self-assessment answer different questions. A consumer perception questionnaire can support a perception claim; it is not a clinical endpoint for wrinkle depth.
5. Sample size, duration and dropouts. A result from a small, short study with heavy dropout is weaker than the same result from a larger, longer, well-controlled study. The FTC lists these as reliability factors.
6. The statistics and the pre-specified analysis. Ask which endpoints were primary, whether the analysis was planned before the data were collected, and whether multiple endpoints were corrected for. A single significant result among many tested outcomes can be chance.
7. Who ran the study, and in what role. Identify the lab, the investigator and the dermatologist's actual involvement. “Reviewed by a dermatologist” is not the same as “a dermatologist designed and supervised the study.”
8. A claim-by-claim map. For each sentence you plan to publish, write down the study, endpoint, time point and population that support it. If a sentence has no row, it has no file.

If any item is missing, downgrade the claim. Do not fill the gap with confidence.

What each phrase commits you to

The table below is a review aid, not a set of statutory definitions. The common thread is that the more specific the promise, the more the evidence has to match it.

Two distinctions matter. First, “tested” is not “proven.” Second, a claim about appearance is not automatically a claim about structure or function. The words around the phrase often decide which category the product lands in.

Red flags in a supplier claim pack

• The “clinical study” is a consumer questionnaire. If participants answered “my skin feels smoother” and nothing was measured clinically, the file supports a perception claim, not a clinical-proof claim.
• The study's time points do not match the promise. A measurement at 12 weeks does not support “visibly younger skin in 7 days” if day 7 was never measured, and a 24-hour hydration reading does not support a four-week wrinkle claim.
• The formula moved after the test. A reformulation can break the bridge between the study and the product on the shelf.
• The percentage has no denominator. “Up to 92%” needs a base, a time point and a description of what “saw results” means.
• The dermatologist is unnamed and the role is vague. A logo and a signature line are not a protocol.
• The before-and-after photos are not comparable. Different lighting, angles, retouching or time gaps can turn an image into an implied claim the study never tested.
• The study is on an ingredient, not the product. The FTC's guidance notes that an ingredient study may not answer what experts would require for the finished product, especially when the product contains other ingredients.
• The deck is stronger than the report. If the conclusion says “supports the appearance of hydration” and the slide says “proves anti-aging,” the slide is the problem.

Before-and-after images, testimonials and image text are claims too

Advertising is not limited to the headline. The FTC's health-products guidance treats packaging, labeling, promotional materials, websites and social media as advertising, and it gives examples in which images alone convey an implied efficacy claim. In one example, before-and-after pictures of a woman with a walker, then dancing, combined with “joint health and mobility” copy, implied that a product could dramatically improve arthritis symptoms. The images did the work even without an explicit disease claim. Elsewhere, the guidance notes that pro forma disclaimers may not cure an otherwise deceptive message.

The same logic reaches the product page. A before-and-after carousel can imply a result even when no sentence states it. A creator's testimonial can imply that an exceptional outcome is typical. Reviews and testimonials have their own rules under the FTC's Consumer Reviews and Testimonials Rule, which we covered separately in the fake reviews rule guide.

Text inside an image deserves its own pass. Some marketplaces restrict promotional text on the main image; that is a separate listing rule. Where text is allowed, the words are still ad copy. Copy the text out of the image and review it with the same claim-by-claim discipline you use for the bullet points.

Where the claim lives

One approved asset does not clear the rest of the campaign. Check each placement:

• Product title and bullets
• Detail images and A+ or rich content
• Video scripts, on-screen text and voiceover
• Creator briefs and talking points
• Landing pages, email and paid social

If a creator makes the claim, the brand can still be exposed. The disclosure and endorsement rules are a separate review; our guide to FTC influencer disclosure covers the disclosure side.

A practical review workflow

1. Extract every objective claim. Put each one in a row: the exact sentence, where it appears, and who owns the evidence.
2. Classify the claim. Appearance, structure or function, disease, or environmental. The category determines which substantiation standard and which regulatory risk apply.
3. Match it to a document. Name the study, the endpoint and the time point. If you cannot name them, the claim is unsupported.
4. Check the product match. Formula, concentration, package and population. Note any gap between the tested product and the sold product.
5. Check the number. Denominator, “up to” range, comparison group and time point. A percentage without a base is not evidence.
6. Rewrite or remove what is left. Prefer a precise, smaller claim over a larger claim with a disclaimer bolted on.
7. Re-check every placement, including images and creator scripts. The claim you fixed in the listing may still be live in a video.

The goal of cosmetic claims substantiation is not a perfect sentence. It is a sentence you can defend with a document.

This is also the point where a wording tool helps — after the evidence review, not instead of it. You can run the final copy through ByeRisk's skincare claim checker to catch phrases that tend to trigger cosmetic-versus-drug or substantiation problems, then send the flagged lines back to the evidence file. For ecommerce teams working across a catalog, the ecommerce compliance workflow is the broader version of the same process. If the same claims appear in short video, review the spoken script separately; the TikTok Shop health claims review walks through that format.

What a checker can and cannot do

A wording checker can flag risky phrases, explain why a sentence reads as a drug claim, and suggest a rewrite. It cannot verify that a study exists, that the study tested the formula you sell, that the endpoint supports the sentence, or that the statistics were analyzed correctly. It cannot guarantee platform approval, restore an account, or establish legal compliance. Those conclusions depend on documents and, in close cases, on advice from a qualified regulatory or legal professional.

Image moderation is not a substantiation review. If a claim is painted into a product image, extract the text and review it as copy. And a clean wording pass does not cure a missing file: the strongest sentence in the world still needs the evidence behind it.

Frequently asked questions

Do I need a randomized controlled trial to say “clinically proven”?

For a health-related benefit, the FTC's guidance says substantiation will generally need randomized, controlled human clinical testing. For a purely appearance-based cosmetic claim, the design can differ, but the evidence still has to be competent and reliable and proportionate to the promise. Adding “clinically proven” raises the bar: you are now claiming clinical proof for that product and that benefit.

Can I say “dermatologist tested” if one dermatologist tried a sample?

Document who tested the product, under what protocol, what was measured, and over what period. A single informal trial is weak support for a phrase shoppers read as a testing claim. FDA does not certify the phrase, so your protection comes from accurate documentation and wording that does not overstate the dermatologist's role.

Is “hypoallergenic” regulated in the US?

FDA states that there are no federal standards or definitions governing the term, that it means whatever a particular company wants it to mean, and that manufacturers are not required to submit substantiation of hypoallergenicity claims to FDA. That does not make the word risk-free: the FTC's truthfulness and substantiation requirements still apply to the comparative message the word sends.

Does “results may vary” make an unsupported claim acceptable?

No. The FTC has said that pro forma statements or disclaimers may not cure otherwise deceptive messages. “Results may vary” can help describe typicality in some contexts, but it cannot turn an unsupported efficacy claim into a supported one.

Can I rely on a study of the active ingredient instead of the finished product?

Not automatically. The study has to support the claim for the product as sold. An ingredient study can help, but you need a reasoned bridge — same concentration, same vehicle, same delivery — and experts in the field may still expect a test of the finished formula.

Sources

• FTC, Health Products Compliance Guidance (December 2022). Reviewed October 18, 2026.
• FTC, Policy Statement Regarding Advertising Substantiation (1984). Reviewed October 18, 2026.
• FTC, “L'Oréal Settles FTC Charges Alleging Deceptive Advertising for Anti-Aging Cosmetics” (June 30, 2014). Reviewed October 18, 2026.
• FDA, Cosmetics Labeling Claims (content current as of November 21, 2022). Reviewed October 18, 2026.
• FDA, “Hypoallergenic” Cosmetics. Reviewed October 18, 2026.
• FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Reviewed October 18, 2026.

This article is editorial analysis, not legal advice. Claim review depends on the product, the evidence and the placement.